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ABSTRACT
Background: Sinonasal malignancies (SNMs) are rare and in Sweden they account for approxi- 
mately 0,1% of all malignancies and 5% of all head and neck malignancies. Apart from sinonasal 
malignant melanoma (SNMM), their incidence has been reported to decrease since 1960 while the 
survival rates have remained rather stable during the same time-period.
Sinonasal inverted papilloma (IP) is a benign tumour with a high risk of local recurrence and a 
potential to malignify. The true incidence of IP is not yet known. From hospital based studies, its 
incidence has been estimated to approximately 0.5/100000 person years. Previous studies have 
reported a malignant transformation of IP in 1–53%. However, it is unknown to what extent IPs are 
associated with squamous cell carcinoma (SCC) on a population basis. 
Also, the aetiology and prognostic factors for IP are mainly unknown. However, human papilloma-
virus (HPV) has previously been suggested as an aetiological factor by some authors. Moreover, 
p16INK4a (p16) overexpression, is often considered as a surrogate marker for high risk HPV in 
oropharyngeal carcinomas, but whether there is a correlation between p16 and HPV in IP and/or the 
prognosis of IP is uncertain. Similarly, a prognostic role of tumour infiltrating lymphocytes (TILs) 
has been observed in many head and neck tumours. However, their role in IP is sparsely investigated.
Prognostic research on cell cycle related proteins such as oncoprotein 18, also called Stathmin, and 
epidermal growth factor receptor (EGFR) is relatively new regarding IP.
In summary, IP is a rare tumour and relevant knowledge regarding factors affecting recurrence, 
malignant transformation and prognosis is still limited.
Aims: The overall aim of this thesis was to investigate possible prognostic factors in IP, more 
specifically HPV, infiltration of TILs and expression of stathmin and EGFR. The aim was also to 
present epidemiological data on IP on a population basis and to describe how incidence and survival 
have changed for SNMs in the Swedish population.
Results:  In total 3221 patients diagnosed with primary SNMs were identified in the Swedish 
Cancer Registry (SCR) from 1960-2010. Their incidence decreased during the study-period except 
for SNMM and adenoid cystic cancer. More than 50 % of the malignancies involved the nasal cavity. 
The five-year relative survival was highest for adenoid cystic cancer followed by adenocarcinoma. 
SNMM and undifferentiated carcinoma had the poorest prognosis. 
In the SCR  814 patients with IP were identified. The incidence of IP increased from 1960 to 2010. 
Patients with IP had an overrepresentation of SCC when compared with the general population 
although this proportion was lower than previously reported. 
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Prognostic factors were analysed in tumours from 98 patients diagnosed with IP in Stockholm between 
2000-2010. In total, 12.2% of the IPs were HPV positive and p16 overexpression was found in the 
only high-risk HPV positive tumour. Patients with HPV positive lesions were younger and tended to 
present with more dysplasia and to relapse less frequently. The tumours also had a higher proportion 
of EGFR expression compared to HPV negative tumours (91.7% and 52.3%, respectively). Stathmin 
was expressed by the tumours cells and not at all or weakly in the normal mucosa and more speci-
mens with dysplasia were stathmin-positive than specimens without dysplasia (40.0% as compared 
to 12.6%). Stathmin positive IPs also tended to have earlier recurrences, although this difference was 
not statistically significant. No correlation was observed between TILs or EGFR and prognosis. 
Conclusions: While the overall incidence of SNM showed a slight decrease, the incidence of IP has 
increased and SCC is less common among patients with IP than previously reported. The results 
suggest that patients with HPV positive and HPV negative IPs may have different clinical 
characteristics, possibly indicating two different disease entities. Stathmin is consistently 
expressed in inverted papilloma but not in the normal mucosa and stathmin positivity seems to 
be associated with dysplasia and possibly also with recurrence. Stathmin might therefore even 
more than EGFR be considered a future therapeutic target.
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INTRODUCTION
SINONASAL MALIGNANCIES
Epidemiology
Malignancies evolving from the sinonasal mucosa covering the nasal cavity and the paranasal sinuses 
are rare and the incidence has been estimated to less than 1/100000 [1, 2]. They account for app- 
roximately 0,1% of all malignancies and 5% of head and neck malignancies in Sweden [3]. The mean 
age at diagnosis is over sixty years, but varies among the different histological types [1, 4]. 
Some studies have shown that apart from sinonasal malignant melanomas (SNMM), sinonasal 
malignancies (SNM) are more common among men but that the incidence among men is decreasing 
and closing in on the female incidence [5-7].
Whether incidence or frequency of the different tumour types has changed over time in the Swedish 
population has not previously been investigated. 
Aetiology
SNMs consist of different histological types and the most common is squamous cell carcinoma 
(SCC). Smoking, alcohol, and formaldehyde seem to be the main aetiological factors associated with 
sinonasal SCC while adenocarcinoma foremost has been associated with exposure to dust from hard 
wood and leather [8-14]. It has also been suggested that sinonasal malignancies are associated to 
heavy air pollution[15]. 
Ebstein Barr virus (EBV) and human papillomavirus (HPV) have been studied as aetiological factors 
for different histological types of SNM but results have been diverging and inconclusive [16-20].
Diagnostic features
Patients with malignancies in the nasal cavity and paranasal sinuses tend to present at a rather 
advanced stage. The symptoms are heterogeneous and non-specific ranging from unilateral 
nasal blockage and epistaxis to septal perforations, ulcers, pain, facial swelling or epiphora [21].Not 
seldom has there been a “doctors delay” and it is important to keep in mind that unilateral symptoms 
and unilateral polyps must be considered malignant until investigation proves otherwise.
Figure 1a: DT scan of an advanced SCC with  
orbital engagement.
Figure 1b: MR picture of the same tumour as figure 1a.
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SNMs are diagnosed by histopathological analysis of tumour biopsies. However, the diagnosis is 
difficult and there is a risk of misclassification [7]. Local spread and metastasis is assessed by 
imaging, both by computed tomography (CT) and magnetic resonance imaging (MRI).
Histological classification
The majority of tumours found in the nose and adjacent sinuses are derived from the mucosa. Some 
tumours such as SCC, adenocarcinoma, undifferentiated carcinoma and transitional cell carcinoma 
derive from the epithelial cells while other tumours derive from cells and glands found within the 
mucosa, for example adenoid cystic carcinoma, mucoepidermoid carcinoma and SNMM. SCC is 
the most common SNM, followed by adenocarcinoma and SNMM [1, 22, 23]. The proportion of the 
different tumour types and how their distribution has changed over time in the Swedish population is 
unknown.
Treatment
 In general, the sinonasal malignancies require a combined treatment with both radical surgery (when 
possible) and radiotherapy (RT) or, more seldom, one of the treatment modalities. There is a con- 
sensus that the treatment of choice for most sinonasal cancers is, whenever required and possible, 
complete surgical resection followed by postoperative radiotherapy with or without chemotherapy 
[24]. Treatment with both surgery and RT is challenging due to the short distance to the brain and 
brainstem, the eye, vital vessels and cranial nerves and both are associated with serious complica-
tions [25]. Because of the rarity of the disease, the many histological types and different tumour 
extension it has been difficult to develop treatment guidelines. However, an international position 
paper has made recommendations of how to manage the different sinonasal malignancies [26]. 
Individual treatment is tailored at multi-disciplinary conferences based on these recommendations.
 
Prognosis
According to an international comparison study, mortality rates between 2004 and 2008 varied from 
1.3 per million in Sweden to 3.3 per million in Denmark [2].
There is a tendency towards improved survival for SNM over time [1, 2]. Patients with SCC of-
ten present with a locally advanced disease and 2-5% have nodal involvement, both contributing 
to a poor prognosis [24, 27]. The improvement of prognosis may possibly be related to the shift of 
location where over time more tumours are diagnosed in the nasal cavity, as compared to the para- 
nasal sinuses [2, 4].
Prognosis for different histological types of SNM other than the most common, SCC, adeno- 
carcinoma and SNMM have not been reported on a population-basis [2, 4, 7]. Women tend to have 
a higher overall survival than men, with a male to female age-standardised mortality rate ratio of 
approximately 2.0 [2].
Among the tumour infiltrating lymphocytes (TILs), T regulatory cells (T-regs) have been studied as 
prognostic factors but the reports are few and no conclusions can be drawn [28, 29]. An association 
between prognosis of SNM and epidermal growth factor (EGFR), among other markers, has been 
reported [30, 31].
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SINONASAL PAPILLOMA
Sinonasal papilloma arise from the ectodermal derived mucosa of the nasal cavity and the paranasal 
sinuses, also sometimes referred to as the” Schneiderian Membrane” [32].
Histologically these are divided into three different groups: exophytic papilloma, inverted papilloma 
and oncocytic papilloma.[33]
 
Exophytic papilloma
Exophytic papilloma, also called everted or fungiform papilloma, are the most common sinonasal 
papilloma and account for approximately 50% of sinonasal papilloma. They often appear in the third 
to fifth decade of life and there is a male predominance. An association with HPV in over 80% of the 
papilloma has been reported in many studies [34-36]. They usually originate from the septal mucosa 
[37]. The exophytic papilloma have a propensity for recurrence but have not been reported to under-
go any malignant transformation. Histologically they typically consist of broad, exophytic branches 
of thickened well-differentiated stratified squamous epithelium surrounding a fibro-vascular core. 
Mucus cells or cysts and microabscesses can be seen throughout the epithelium [37]. 
Inverted Papilloma
Inverted papilloma (IP) is also called transitional cell papilloma, inverting papilloma and 
Schneiderian papilloma although all papilloma can be referred to as Schneiderian. IP represent 
less than 50% of the sinonasal papilloma. IP is a benign neoplasm originating from the sinonasal 
mucosa with an extensive growth-pattern, a risk of recurrence and an association with malignant trans- 
formation as will be described. 
Oncocytic papilloma 
Oncocytic papilloma, also called cylindrical cell papilloma, have enlarged epithelial cells that 
possess abundant mitochondria resulting in a granular eosinophilic cytoplasm[33]. They are rare 
and account for approximately 5% of sinonasal papilloma. They usually originate from the lateral 
nasal wall. There is no difference in incidence due to gender and they often appear in the 5th-6th 
decade of life. Oncocytic papilloma can be associated with SCC or mucoepidermoid cancer [38]. They 
exhibit both exophytic and endophytic patterns with several layers of pseudostratified columnar cells 
containing uniform small dark round nuclei and eosinophilic cytoplasm. Intraepithelial mucinous 
cysts and microabscesses can be detected [37].
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INVERTED PAPILLOMA
Incidence and epidemiology
The incidence of IP varies in different studies, most of which are not population-based, but has been 
estimated to approximately 0,5-1.5/100000 person-years (py) [39, 40]. According to the number of 
referrals of patients with IP, the incidence seems to have increased [41]. The age of onset varies 
widely, from adolescence to over 90 years, but the highest incidence is during the fifth-sixth decades 
of life with a reported male to female ratio of 2:1 to 5:1 [42, 43].
Aetiology
Different aetiological factors for inverted papilloma have been proposed, such as smoking, outdoor 
and industrial occupations and chronic rhinosinusitis [33, 44, 45]. A viral association of EBV virus 
has also been presented[46]. HPV has been proposed as an aetiological factor although the results 
and interpretations of its involvement in the development of IP are very diverse ranging from no 
association to a high association [47-49]. Thus, there is presently no consensus regarding the 
association of IP with HPV or whether HPV is an aetiological factor for IP or not. 
Diagnosis
Diagnosis is made by clinical examination with endoscopy, biopsy for histological analysis and 
imaging for evaluation of tumour extension [26]. 
Symptoms and clinical findings
Patients with IP have unspecific symptoms, most often unilateral nasal obstruction, less commonly a 
unilateral nasal mass, epistaxis, sinusitis, anosmia, rhinorrhoea or pain [37, 43]. If the tumour engages 
the sphenoid sinus patients can suffer from neurological or visual symptoms  [50]. In rare cases IP 
has grown into the orbit or skull base where patients have presented with related symptoms such as 
diplopia and headache [51]. Some patients are asymptomatic and their tumours are found en passant.
IP is best visualised endoscopically. The IP is often cerebriform, pink-greyish, firm, bulky and 
lacks translucency (Figure 2) [52]. This differentiates them from the sinonasal polyps. However, 
they may have a polypoid appearance and IP or malignancy should be suspected in all patients with 
uni-lateral polyposis. Polyps should therefore be sent for histology to avoid misdiagnosing of 
an IP or a malignancy [53, 54]. Because IP often is slow-growing, there is often a patient delay 
with an estimated mean duration of 3,9 years [55]. 
Figure 2: Endoscopic view of IP.  
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Figure 3: Advanced recurrence of IP with destruction of the 
hard palate.
Imaging
Radiological imaging serves the purpose of determining the extension of the tumour and to 
identify the original site for the upcoming surgery. CT is the primary imaging modality and typically 
shows a unilateral homogenous mass extending from the middle meatus through a widening of the 
maxillary ostium to the adjacent maxillary sinus. Bone erosion can be found in IP but malignancy 
must be suspected, especially when there is considerable bone destruction. Hyperostosis is highly 
correlated to the site of origin of the tumour and calcifications are common and can be seen in 
approximately 20% of cases [56-58]. 
It can be difficult to determine tumour from inflamed mucosa or retained mucus why MRI is a helpful 
complement. On MRI, IP can appear as cerebriform circumvolutions, often with a columnar pattern, 
and remodelling of the bone can sometimes occur [59, 60].
Histology
A biopsy is always warranted for histological evaluation. In inverted papilloma, the epithelium 
inverts into the underlying stroma but with a preserved basement membrane. Histologically the 
invaginating sinonasal columnar epithelium undergoes squamous metaplasia and therefore it can 
be variably squamous, squamoid, transitional or ciliated columnar. The thickened epithelium has a 
prominent down-growth of elongated, rounded epithelial masses sometimes exhibiting an elephant 
foot appearance (figure 4) [61].The desmosomes (intercellular bridges) are preserved. Some IPs have 
mitotic figures but never atypical or numerous. Microscopic cysts are seen throughout the neoplastic 
epithelium containing cell debris, macrophages and mucin [32]. Neutrophil infiltration is seen in a 
majority of cases along with microabscesses. Areas of mild to severe dysplasia can occur, with cells 
characterised by anisocytosis, poikilocytosis, hyperchromatism and presence of mitotic figures [37, 
62]. 
Figure 4: Histological appearance of IP.
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Site of origin
IPs most often have their site of origin on the lateral wall of the nasal fossa, the maxillary sinus and 
the ethmoid region. The frontal and sphenoid sinuses are less commonly seen as site of origin [63]. 
Not rarely does IP extend into adjacent sinuses. It has also been reported that IPs extend into the orbit. 
However, this should give rise to suspicion of malignancy as should a bilateral manifestation of the 
tumour whereas IP most seldom is bilateral [64, 65].
Staging
In the three major staging systems, Krouse, Han and Cannady, the stage is defined according to the 
location and the extent of the tumour and Krouse also includes associated malignancy (Figure 5 a- c) 
[66-68]. Krouse is the most commonly used staging system and tumour stage is believed to correlate 
with outcome [69]. However, a new study suggests that Han and Cannady better predict recurrences 
[70].
Krouse Staging system
T1 IP is confined to the nasal cavity.
T2 IP involvement of the ostiomeatal complex, ethmoid sinus, and/or medial maxillary sinus; with or without involvement of the nasal cavity.
T3 IP involvement of lateral, inferior, superior, anterior, or posterior walls of the maxillary sinus, the sphenoid sinus, and/or the frontal sinus.
T4 IP involvement beyond the sinonasal cavities or associated with malignancy.
Figure 5a: Krouse staging system66
Cannady Staging system
Group A IP is confined to the nasal cavity, ethmoid sinuses and/or medial maxillary wall.
Group B IP involvement of any maxillary wall (besides the medial wall), frontal sinus or 
sphenoid sinus.
Group C IP involvement beyond the sinonasal cavities.
Figure 5b: Cannady staging system67 
Han Staging system
Group I IP is confined to the nasal cavity, lateral nasal wall, medial maxillary sinus, ethmoid sinus and/
or sphenoid sinus.
Group II IP involvement of lateral to medial maxillary wall.
Group III IP involvement of the frontal sinus.
Group IV IP involvement beyond the sinonasal cavities.
Figure 5c: Han staging system68
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Treatment
IP is treated by surgery. During surgery, it is important to resect the entire tumour with adjacent 
normal mucosa, to drill underlying periosteum and hyperostotic bone at the attachment site of the 
tumour and to remove all affected bone to minimise the risk of recurrence [71]. 
Previously, IP was considered best treated with an open en bloc resection. Since the 1980s the 
endonasal endoscopical approach has evolved and is now advocated for the majority of cases 
because of better visibility, good access and less morbidity than with an open approach without 
affecting the recurrence rate negatively. Sometimes it is combined with an external approach, 
depending on the location and extent of the tumour. Most authors agree that tumours limited to 
the middle meatus, ethmoids, middle maxillary wall, sphenoid, frontonasal recess, medial frontal 
sinuses and skull base can be managed endoscopically [69, 72]. The resection should also permit a good 
endoscopic view of the tumour area for future follow-up. Radiotherapy has no place in the treatment 
of IP except for rare, difficult or recurrent cases [73].
Recurrence
IP has a high propensity for recurrence, often estimated to approximately 15-30%, but the recurrence 
rate varies largely in different studies [43, 74, 75]. However, even though factors such as location, 
multicentricity and extent of tumour growth affect the results, recurrences are much related to the 
surgical treatment and to what extent the IP is radically resected [76]. Most recurrences occur within 
the first two to three years at the original site [77]. In a meta-analysis from 2006, contemporary 
recurrences after endoscopic resection was 12% vs 20% for non-endoscopically treated IPs [78]. 
Because of the relatively high recurrence rates in IP, patients should be followed for at least three 
years [26, 65]. Previous recurrences, risk of inadequate resection or signs of aggressive behaviour of 
the tumour should impel physicians to prolong the follow-up time.
Malignant Transformation
An association between IP and SCC, mainly well-differentiated SCC, has been identified[79]. It 
can sometimes be difficult to separate IP from cancer. Histological signs of malignant transforma-
tion are increased hyperkeratosis, squamous hyperplasia, increased nuclear to cytoplasmic ratio, 
atypical mitosis, high mitotic index, and especially loss of polarity and invasion through the basement 
membrane [80, 81]. Radiologically, significant bone erosion or bone destruction and focal loss of 
cerebriform pattern are malignant signs [82].
Different studies show diverging results regarding the proportion of IP that malignifies but most 
articles report a malignant transformation of approximately 5-10 % [83, 84]. SCC is found both 
synchronously and metachronously (diagnosed in the same area as the IP but later). In a review 
from 2010, 6,8% of patients with IP had synchronous carcinomas while 3% developed metachronous 
carcinomas [26].
Many factors have been studied for their role in the pathogenesis of the malignant transformation of 
IP [85]. HPV is among the most studied but the results are diverging and whether HPV has an active 
role in the malignant transformation of IP or not is still unclear [86]. Other markers such as over- 
expression of oncoproteins, p16, p53, EGFR have been proposed as causative factors although their 
roles as such remain uncertain [86-88].
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HPV
Background
There are over 200 different types of HPV which all belong to the papillomaviridae family. The 
papillomaviridae family includes 16 different genera where the human papillomaviruses belong to 
five of the genera (alpha, beta, gamma, mu and nu). Among these the beta genus contains most 
HPV types associated with cutaneous tumours while the alpha genus contains the viruses mainly 
associated with the development of mucosal tumours. The alpha HPV can be divided into low risk 
(LR) and high risk (HR) depending on their ability to induce malignancies. LR HPV can give rise to 
benign conditions such as anogenital warts and respiratory papillomatosis (HPV6 and HPV11) and 
common skin warts (HPV1 and HPV2) [89]. 
Types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 are listed as HR by the International Agency 
for research on Cancer (IARC)/ World Health Organization (WHO) for their causative role in the 
development of especially cervical cancer, anogenital cancer and oropharyngeal cancer [90, 91].
Viral structure
HPV is a small (55nm in diameter) non-enveloped, capsid-encased, double-stranded DNA virus with 
a genome of approximately 8000 base pairs. The genome consists of an early region (E), that codes 
for E1-2 and E4-7 proteins, required for viral gene expression, replication and survival, a late region 
(L) coding for the capsid proteins L1 and L2, and a long control region (LCR), a non-coding region 
which regulates the viral gene expression and replication.
HPV and carcinogenesis
 HPV is transmitted from skin-to-skin or mucosa-to-mucosa. In cervical infections, it is transmitted 
sexually but in oropharyngeal infections the route of transmission is not as clear although sexual 
contact has been suggested [92]. The transmission route to the sinonasal mucosa is sparsely studied. 
HPV infects the mucosal epithelial cells in the basal layer. This mechanism is not fully understood 
but possibly by entry through micro traumatised epithelium [93]. Often, HPV-infection heals by 
interference of the human immune response but in a minority of cases the infection results in an 
asymptomatic carrier state which later may lead to dysplasia and malignancy. The replication of the 
HPV virus takes place in the host nucleus, dependant on S-phase entry [94]. The integration of the 
viral genome leads to expression of its three oncoproteins; E5, E6 and E7. These oncoproteins play a 
key role in the malignant transformation. 
• The mode of action for E5 is still unclear, but in vitro studies have showed that E5 may increase 
EGFR levels as well as modulate the EGFR signalling pathway. E5 can thereby exhibit a weak 
transforming activity [95]. The E5 coding sequence is often deleted from the viral DNA during 
integration into the host genome. Therefore, E5 may not be required for the late stage of carcino-
genesis in the significant way that are E6 and E7 [96]. 
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• E6 cooperates with E7 and affects the cell apoptosis process thereby promoting viral DNA 
replication. The most well characterized target of E6 from high-risk HPV types is the tumour- 
suppressor protein p53. P53 usually acts by arresting cells in G1 to allow host DNA to be 
repaired or else to undergo apoptosis. E6 protein forms a complex with an E3 ubiquitin ligase and 
ubiquinates (degrades) p53. Cells expressing E6 thereby lose their p53 checkpoint function and 
are therefore susceptible to genomic instability [96]. 
• E7 binds to the cullin 2 ubiquitin ligase complex and ubiquitinates the retinoblastoma tumour 
suppressor protein (pRb). This induces degradation of pRb resulting in uncontrolled G1/S phase 
of the cell cycle. The absence of the pRb function induces a release of transcription factors and 
transcription of S-phase genes occurs, leading to cell proliferation. In summary, in a HPV infected 
cell, pRb is inactivated by E7 and consequently S-phase is induced [96]. The inactivation of pRb 
results in an overexpression of p16INK4a (p16) since pRb normally inhibits transcription of p16. 
Upregulation of p16 can also be mediated by E7 independently from pRb inactivation. 
HPV and p16
HR HPV positive malignant tumours, especially cervical, oropharyngeal and anogenital cancers, are 
often p16 positive [97, 98]. Hence p16 is frequently used as a surrogate marker for HPV in these 
tumours [99]. However, its function as a surrogate marker in OPSCC is under debate [100, 101]. 
Furthermore, its role as surrogate marker in IP has not been assessed. 
HPV and immune response
When infected by a virus, keratinocytes start secreting pro-inflammatory cytokines. This attracts 
antigen-presenting cells such as dendritic cells (DC) and macrophages. DCs also engulf viral 
products. This promotes DC activation. Mature DCs migrate to the lymph nodes where they present 
the foreign HPV proteins, degraded into peptides, on the major histocompability complex (MHC, 
in humans also referred to as human leukocyte antigen-HLA). Upon presentation, DCs also bind 
to cytotoxic T cells or helper T cells and interact with and activate their respective CD8+ or CD4+ 
receptors. CD4+ cells mature into Th1 or Th2 cells where the Th1 cells help promote maturation of 
CD8+ cells and activate macrophages and NK cells [102].
It has been suggested that the T cell response, comprising both CD4+ and CD8+ cells, are required 
to kill HPV infected cells. An immune response with infiltration of TILs in HPV-positive OPSCC has 
been correlated with clinical outcome and it would be beneficial to determine if the same relation is 
valid for IP [103, 104]. 
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HPV detection methods
There are three methods mainly used for detection of HPV; polymerase chain reaction (PCR), in situ 
hybridisation (ISH) and detection of p16 by immunohistochemistry (an indirect method). Detection 
of viral proteins and serum anti bodies against viral proteins can also be used.
• Polymerase chain reaction (PCR): PCR is often done with a consensus primer, also called, general 
primer, that’s to say a primer that can detect different HPV types by binding to highly conserved 
regions within the viral genome. Among these, broad spectrum Gp5+/6+ is often used because of 
its high sensitivity [105]. After DNA amplification, commonly a probe-based technique is used to 
type the PCR product (eg Luminex) [106]. 
• In situ hybridisation (ISH): In ISH, a biotinylated probe is hybridised to the viral DNA, after 
which the signal is amplified. The presence and localisation of the virus is thereafter visualised 
under a light microscope [107].
• detection of p16 by immunohistochemistry (IHC): p16 is most often upregulated in HPV infected 
cells and often lost in HPV negative tumours [107]. It is therefore used as surrogate marker. IHC 
is an antibody-based method to identify proteins in tissues and cells. The indirect method where 
antibody-protein conjunction is detected with an enzyme-labelled polymer conjugated secondary 
antibody, has a better sensitivity than the direct method where a labelled antibody reacts directly with 
the antigen. After incubation with a substrate, a positive immunoreactivity occurs. If 3,3-diamino-
benzidine (DAB) is used as substrate, a brown colour can be seen. To provide contrast to the sections 
and to visualize the nuclei, the slides are usually counter stained with haematoxylin. To rule out 
unspecific background staining, negative controls for mouse and/or rabbit primary antibodies 
 are used. To summarise, a solution with fluorescence marked antibodies are added to tumour 
tissue and thereafter visualised by microscopy. The value of p16 as a surrogate marker in HPV 
associated malignancies is as mentioned under debate. Since approximately 14% of HPV 
negative oropharyngeal tumours have upregulated p16, the use of p16 as surrogate marker for 
HPV in OPSCC should not be advocated [100].
HPV in sinonasal SCC and IP
Some reports have found an association between HPV and SCC and suggest that HPV is a positive 
prognostic factor [91, 108]. It has also been suggested that HPV is associated with the prognosis of 
IP and that HPV positive IP has an increased risk of recurrence and malignant transformation [109, 
110]. Although, for IP, as opposed to malignant tumours, LR HPV positivity has mainly been reported 
[111].
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TUMOUR INFILTRATING LYMPHOCYTES (TILs)
Tumour infiltrating lymphocytes are B cells and T cells who have left the bloodstream and infiltrate 
the tumour or its stroma. They have, for different malignancies such as breast cancer, colon cancer, 
malignant melanomas and head and neck cancers, been associated with tumour prognosis and clinical 
outcome [112, 113].
CD8 positive T cells
CD8 is a protein expressed by, and thus a marker for, cytotoxic T cells. These are lymphocytes which 
can kill endogenous cells, with help from the CD4+ T regulatory cells, by induction of apoptosis or 
by cell lysis. Cytotoxic T cells have the ability to destroy virus-infected cells and tumour cells. Cells 
infected by viruses synthesize viral proteins presented on its MHC-1 molecule, to which the T cell 
can bind.
It seems that a high level of CD4+ and CD8+ TILs improves overall survival in head and neck 
squamous cell carcinoma (HNSCC) [114]. This phenomenon is seen in many solid tumours. It has 
further been shown that the morphological pattern of TILs is important and that it differs between 
HPV positive and HPV negative cancers [115, 116].
Forkhead box protein 3 positive T cells
Forkhead box protein 3 (Foxp3) is expressed by a subgroup of the CD4+ T helper cells called 
T regulatory cells (T-regs). They control and regulate the specific immune response, inhibit the 
activation of T helper cells and suppress the antigen presenting cells so that the T helper cells are 
deprived the signals promoting mitosis and maturation. Instead tolerance towards the antigen 
appears. Studies indicate that in viral infections, the protective function of CD8+ T cells is com- 
promised by the presence of Foxp3+ cells [117]. 
According to some reports, tumour infiltration of Foxp3+ TILs improves survival while others have 
found that a high CD8+/Foxp3+ ratio is beneficial [103, 114, 118]. 
CD8 and Foxp3 in IP
CD8+ and Foxp3+ TILs might be prognostic factors in head and neck malignancies. Although 
seemingly frequent in IP and in associated SCC they are sparsely studied in those tumours. 
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BIOMARKERS
Biomarkers are defined by the National Cancer Institute (NCI) as a biological molecule found in 
tissue, blood or body fluids that is a sign of a normal process, a condition or a disease [119]. They can 
be used to measure level of disease or effect of treatment and some markers, like EGFR and stathmin, 
are proteins related to the cell-cycle.
Epidermal growth factor receptor 
The EGFR is a trans-membranous tyrosine kinase cell surface receptor belonging to the erbB 
family. EGFR is activated when its ligands, among them epidermal growth factor (EGF) and tumour 
growth factor-a (TGFa), bind to its extracellular parts leading to its dimerization. This stimulates 
phosphorylation of tyrosine kinase which in turn activates numerous signalling pathways leading to 
a modulation of functions such as DNA synthesis, cell migration, cell proliferation, angiogenesis and 
apoptosis [120]. 
EGFR and tumour prognosis
Overexpression and mutation of EGFR is associated with a wide variety of tumours and a poorer 
prognosis [121]. Interruption of EGFR signalling, either by blocking EGFR binding sites on the 
extracellular domain of the receptor or by inhibiting intracellular tyrosine kinase activity, can prevent 
the growth of EGFR-expressing tumours and improve the condition in head and neck cancer patients 
[122].
Stathmin
Stathmin is an oncoprotein (oncoprotein 18) important in the regulation of the cell cycle. During 
the M-phase of the cell cycle, the mitotic spindle, composed of microtubules built up by alfa- and 
beta- tubulin, is responsible for aligning the cell chromosomes, segregating the cell chromatids to 
form two identical sister cells. Polymerisation and depolymerisation of microtubules respectively 
causes it to grow and disintegrate. Stathmin, when binding to tubulin, inhibits polymerisation and 
microtubule assembly. When stathmin is phosphorylated the level of tubulin in the cytoplasm 
increases and this promotes microtubule assembly [123].
 
Stathmin and tumour prognosis
When mutated or abnormally activated, stathmin can cause transformation of normal cells to 
cancerous cells by uncontrolled proliferation. If stathmin is unable to bind to tubulin, it allows 
constant microtubule assembly and therefore constant mitotic spindle assembly. With a deficient 
regulation of the mitotic spindle, the cell cycle is capable of cycling uncontrollably leading to 
unregulated cell growth characteristic of cancer cells.
Mutation and overexpression of stathmin has shown to be associated with numerous human cancers 
and their prognosis [123, 124]. 
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EGFR and stathmin in IP
In the few studies investigating the association between EGFR and IP, it seems that overexpression or 
mutation of EGFR is associated with IP and of SCCs derived from IPs, as opposed to SCCs without 
IP  [125-127]. The one study assessing the association between EGFR and HPV in IP found EGFR 
mutations and HPV to be mutually exclusive prognostic factors in IP [128]. Since stathmin is an 
oncoprotein and associated with prognosis of malignancies it is an interesting marker to study in IP. 
However, reports on the association between stathmin and IP are sparse. One study found stathmin 
to be a valuable prognostic marker [129]. Therefore, further investigations on stathmin and IP are 
warranted.
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AIMS OF THE THESIS
The overall aim was to study the incidence trends of SNM and IP and also the malignant 
transformation and prognostic factors of IP on a population basis.  
Specific aims:
Paper I:  The aim of this study was to determine the incidence trends and  
survival trends for different histological subgroups of SNM in 
Sweden 1960-2010.
Paper II:  In this study, the intent was to investigate the changes in incidence 
and the malignant transformation of IP on a population-basis, in 
Sweden 1960-2010.
Paper III:  The purpose was to analyze the presence of HPV and the infiltration 
of CD8+ T cells and Foxp3+ T-regs in specimens of IP and to analyze 
their correlation to prognostic outcomes. The possibility of using p16 
as a marker for high risk HPV in IP was also investigated.
Paper IV:  This study aimed to assess if stathmin or EGFR correlate with HPV, 
dysplasia or recurrence of IP.  
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MATERIALS AND METHODS
SUBJECTS AND MATERIALS
All studies were conducted according to the ethical permission 2012/49-31/2 from the Regional 
Ethical Review Board at the Karolinska Institute, Stockholm, Sweden. 
Paper I. Patients were identified from the Swedish Cancer Registry (SCR). All patients diagnosed 
with SNM between 1960-2010 with the codes 160.0, 160.2, 160.7, 160.8 and 160.9 according to 
the ICD-7 were included. The SCR has a coverage of approximately 96% of all cancers diagnosed 
in Sweden but the coverage was more uncertain during the first two years of its existence (1958-
1959). Therefore, patients diagnosed from 1960 onwards were included [130, 131]. From the SCR, 
we also retrieved information on the patients gender, age at diagnosis and the histological type and 
localisation of the tumours.
Information on the patients identified in the SCR from the emigration, immigration and causes of 
death registers, from Statistics Sweden enabled identification of patients lost to follow-up and to 
perform survival analysis. For the survival analysis, patients were followed until the end of 2012. 
From Statistics Sweden (Statistical Yearbook of Sweden) information on annual population and 
gender distribution to calculate incidence rates was retrieved.
Paper II. From the SCR, patients with tumours diagnosed from 1960-2010 with the histology 
code for true papilloma, in the sinonasal area, numbered 160.0, 160.2, and 160.7–160.9 according 
to the ICD-7 were included and information on their gender distribution and age at diagnosis was 
collected. Data was also retrieved on patients with IP who were diagnosed with SCC in the sinonasal 
mucosa synchronously or later than the IP diagnosis. Information for analysis of loss to follow-up and 
information for calculations of incidence rates were obtained from the same registers as in paper I.
Paper III. Subjects were patients diagnosed with IP in Stockholm 2000-2010 identified from the 
SCR. The study base consisted of 126 patients. Formalin fixed, paraffin embedded (FFPE) blocks 
with specimens of IP from these patients were obtained from the Stockholm Medical Biobank (SMB). 
After histological re-evaluation of the original diagnosis by a qualified pathologist for the cases where 
blocks were not missing or slides not unusable, 98 cases out of 126 were obtained for further analysis. 
Patient data including age at diagnosis, gender, recurrence data, follow-up time, malignant trans- 
formation and information on reported surgical margins was obtained from the medical records. 
Tumours where the surgeon reported uncertain radicality of the tumour resection or where the 
question of radicality was not mentioned were considered as having positive surgical margins. Data 
on dysplasia were obtained from the histopathological reports.
Paper IV: Subjects and their clinical data were the same as for paper III.
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METHODOLOGY
HPV DNA detection by PCR
In paper III-IV, HPV DNA was extracted from 30μm sections (2x15μm) from FFPE IP tumour blocks. 
DNA was purified using the Roche High Pure FFPET DNA Isolation kit (Roche Diagnostics GmbH, 
Mannheim, Germany) according to the manufacturers instructions. Blank controls were included in 
parallel to detect cross-contamination.
The DNA detection method consists of a multiplex PCR followed by a Luminex-based assay for 27 
HPV types, described below [105, 106].
For the PCR, broad-spectrum general primers, GP5+/6+ primers (BGP5+/BGP6+) were used. These 
bind to the well-conserved L1 region of the HPV genome. 10µl of extracted DNA from the FFPE 
material (tumour or blank control) was added to a 50μl reaction mixture containing biotinylated 
primers in the HPV genotyping kit and Qiagen Multiplex PCR Master Mix (Qiagen, Hilden, 
Germany). A denaturation step during 15 minutes at 94°C was followed by 40 cycles of ampli- 
fication. These cycles each consisted of a denaturation step of 20 seconds at 94°C, an annealing step 
at 38°C during 90 seconds and an elongation step at 71°C during 80 seconds. The final elongation step 
of the last cycle lasted for 4 minutes [115]. DNA from SiHa cells were used as HPV-positive control 
and primers of the housekeeping gene ß-globin were used to confirm presence of amplifiable cellular 
DNA. RNAse free water was used as a negative control.
The amplified DNA was then analysed using a bead-based assay in a Magpix instrument (Luminex 
Corp). The assay covers 27 HPV types (HPV 6, 11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 43, 44, 45, 51, 
52, 53, 56, 58, 59, 66, 67, 68, 69, 70, 73 and 82) and ß-globin. To summarize, magnetic beads with 
27 different colours were attached to probes specific for, in this case, DNA of the 27 HPV types. The 
PCR products were denaturised and hybridized to the bead-probe complex. Unhybridized DNA was 
washed away and the PCR products were stained with a fluorescent dye. After another washing, the 
complexes were analysed in the Luminex 100 analyzer (BioRad Laboratories, Hercules, USA) by 
two lasers. One laser evaluated the colour of the beads, hereby determining which HPV types were 
present. The second laser detected the fluorescent dye and semi-quantified the amount of DNA so that 
the result was expressed as median fluorescence intensity [106].
Immunohistochemistry 
The IHC procedure consisted of 4µm FFPE sections which initially were de-paraffinised in 
xylene and rehydrated in ethanol followed by antigen-retrieval in citrate buffer in a microwave oven. 
Thereafter, endogenous peroxidase activity was extinguished with hydrogen peroxide and the 
slides were treated with horse serum to block unspecific binding sites. Then the slides were 
incubated with the primary antibody (see below) after which a biotinylated secondary anti-mouse 
antibody (anti-rabbit for EGFR) was applied followed by incubation with an avidin-biotin complex. 
The slides were then developed in DAB 3.3’ diaminobenzidine (DAB) and counterstained using 
haematoxylin. Evaluations were done using light-microscopy with researchers blinded to clinical 
data and prognosis related to the tumours assessed. Discrepant opinions were solved by consensus.
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p16
p16INK4a overexpression was analysed using the p16 antibody (clone E6H4, undiluted, CINtec®, 
Ventana CINtec® p16 Histology, Roche AB, Stockholm, Sweden). The fraction of positive cells and 
staining intensity were evaluated and a consensus was formed for each sample. p16 positivity was 
defined as a strong and diffuse cytoplasmic and nuclear staining in >70% of all cells of the lesion 
[132]. 
CD8+ and Foxp3+ infiltrating lymphocytes
Analyses of CD8 and Foxp3 positive immune cells were performed in a similar way using the 
mouse monoclonal antibodies anti-CD8 (dilution, 1:40; clone 4B11; Novocastra Laboratories) and 
anti-Foxp3 (dilution 1:100, clone 236A/E7; eBioscience) respectively [103]. CD8 and Foxp3 positive 
immune cells infiltrating the lesion were evaluated by counting positive cells in 10 randomly selected 
high-power fields (40×) per sample. The ratio of tumour infiltrating CD8+ and Foxp3+ cells was also 
calculated for every lesion.
EGFR
EGFR expression was analysed using the rabbit monoclonal antibody, anti- EGF Receptor XP® 
(clone: D38B1, dilution: 1:50, Cell Signaling, Massachusetts, USA) [101]. Positive EGFR staining 
was defined as membranous staining with strong intensity. Fraction of EGFR positive tumour cells in 
the slide (closest 10%) was evaluated. 
Stathmin
Stathmin expression was analysed using anti-Stathmin 1 RabMab® (clone: EP1573Y, dilution: 1:250, 
Abcam, United Kingdom). Positive stathmin staining was defined as a strong cytoplasmic staining. 
Fraction of stathmin positive tumour cells in the slide (closest 10%) was evaluated. 
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STATISTICAL ANALYSIS
Paper I. The subjects included were divided into three different age groups; <55, 55-69, ≥70. For 
the incidence-rates, the calendar period was divided into five-year-periods. Incidence rates were 
calculated by dividing the number of cases by the total population in each age group for every 
five-year-period. The rates were adjusted both to the World Standard Population of 1966 and the 
Swedish Standard Population of year 2000.
Relative survival was further analysed, defined as the observed survival in the study- population 
divided by the expected survival of a group in the general population comparable regarding age. 
The relative survival thereby measures excess mortality as a result of cancer without relying on 
information on cause of death[133]. To estimate the expected survival, the Ederer II method was 
applied on data from the Swedish population life tables stratified by age, gender and calendar 
period [134]. Relative survival was analysed by decade and the three defined age-groups were 
used to estimate the age-standardized relative survival [135].To adjust for effects of age at 
diagnosis, year of diagnosis and gender on the excess mortality rate ratio a multivariable Poisson 
regression analysis was conducted. 
Paper II. Because of the low incidence of IP, the incidence was reported per decade. The study period 
was divided into decades beginning in 1960. Incidence rates were calculated by dividing the number 
of cases in each calendar period by the total average population in each age group for each decade. 
The incidence rates were calculated for the population as well as sex specifically. For comparison, the 
rates were also age-adjusted to the Swedish Standard Population of year 2000.
The incidence of SCC among patients with IP was calculated as a proportion and a standardised 
incidence ratio (SIR). SIRs were calculated for SCC in patients diagnosed with IP by dividing the 
observed numbers of SCC in this group by the expected numbers of SCC based on person-years at 
risk and population incidence. 
Paper III. For differences in categorical date we used the Pearson Chi-square and the Fisher exact 
test and for continuous data, the Mann Whitney U-test. Time to recurrence was measured from the 
date of diagnosis until a documented recurrence of IP, when the patients were considered a case. 
Patients lost to follow up or dead were censured. All patients were considered as tumour free after 
surgery, independent of reported surgical radicality. Patients without any follow-up were censored 
day 0. The Kaplan-Meier estimator was used to estimate survival and differences in survival was 
assessed using the log-rank test. Hazard ratios (HR) for recurrence were calculated by univariable and 
multivariable Cox regression. The multivariable model included age, gender, HPV and radicality as 
covariables.
Paper IV. Pearson Chi-square and the Fisher exact test was used for categorical data and the Mann 
Whitney U-test was used for data which did not have a normal distribution. Recurrence was assessed 
in the same way, by the Kapplan-Meier estimator and Cox regression analysis.
P-values of <0.05 were considered statistically significant in all studies.
For paper I and II, statistical analysis was performed in SAS 9.2, STATA (StataCorp, 4905 Lakeway 
Dr, College Station, TX 77845, USA), and Excel. In paper III and IV, SPSS (SPSS Statistics for Mac, 
Version 21.0. Armonk, NY: IBM Corp. USA) and STATA (StataCorp, 4905 Lakeway Dr, College 
Station, TX 77845, USA) were used.
30 31
RESULTS 
PAPER I
Frequency of sinonasal malignancies
3 221 patients with non-lymphoid SNMs were included. The mean age at diagnosis occurred during 
the seventh decade of life for all histological subtypes except for SNMM which had the highest mean 
age at diagnosis (71.7 years). 
The predominant histopathological type was SCC followed by adenocarcinoma and SNMM. There 
was a male predominance except for SNMM and adenoid cystic carcinoma, where the female gender 
was predominant (55% and 53%, respectively). 
The two most common anatomical localisations for the tumours were the nasal cavity (49.9%) and 
the maxillary sinuses (31.4%). During the study period, the proportion of tumours originating from 
the nasal cavity compared to tumours from the maxillary sinuses increased. SNMM had a higher 
frequency of tumours located in the nasal cavity compared to SCC. 
Incidence of sinonasal malignancies 
The incidence rate of SNM decreased from 1.19 in the first decade of the study period to 0.86/100000 
py in the last decade studied and the trend observed was similar for men and women. The incidence 
of SCC as well as undifferentiated carcinoma decreased whereas SNMM was the only sinonasal 
malignancy that increased in incidence (from 0.04 to 0.15/100000 py) during the study period. This 
resulted in a shift in distribution of histological types of SNM (Figure 6a and 6b).
Figure 6a:  Proportion (%) of different histological types 
of sinonasal malignancies 1960-1969. 
Figure 6b: Proportion (%) of different histological types of 
sinonasal malignancies 2000-2010.
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Survival rates for sinonasal malignancies 
The 5-year relative survival data was evaluated for all patients diagnosed from 1960 to 2010. 
36 patients were lost to follow-up. The overall relative survival tended to improve during the 
study period. This trend was seen among all histological types except for sinonasal undifferentiated 
carcinomas.
The patients with adenocarcinoma and SCC had a 5-year relative survival of 56% and 46%, 
respectively. SNMM and undifferentiated carcinoma were associated with a poorer prognosis 
with 5-year relative survival of 27% and 37%, respectively. Patients with adenoid cystic cancer 
had the best 5-year relative survival (58%). Regarding survival in relation to localisation of the tu-
mour, patients with tumours originating from the nasal cavity had a better prognosis than patients 
with tumours originating from the maxillary sinuses (mean overall survival time 84.2 versus 55.2 
months; p < 0.0001). 
PAPER II
The mean age at diagnosis for IP was 55.1 for the whole study population, 54.7 for males and 56.1 
for females, and was stable over time. The male-to-female ratio was also rather constant over time 
from the seventies onwards (2.4–3.3:1). The incidence of IP increased over time from 0.01/100000 
py in the sixties to 0.33/100000 py in the first decade of this century (figure 7). The same trend was 
observed for males and females. 
In all, 814 persons were diagnosed with IP during the study period. Among them, 11 (1.35%) were 
diagnosed with SCC or SCC in situ. This corresponds to an incidence of SCC over the time period 
of 111/100000 py among patients with IP as compared to 0.37/100000 py in the general population. 
Only in males did IPs undergo a malignant transformation, which was statistically significant. For men 
with IP, this represented a proportion of 1.88% that developed SCC or an incidence of 157.8/100000 
py as compared with 0.46/ 100000 py in the general male population. 
For the whole IP cohort, the SIR was 142.76 (p <0.05), which also demonstrates an over-represen-
tation of SCC among patients with IP. When analysing the SIR stratified by duration, we found no 
evidence of reverse causality. 
Figure 7:  incidence of IP /100000 py 1960-2010
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PAPER III
Of 126 patients reported with IP during the period, 28 cases were excluded from the study because 
they were re-evaluated as non-IP, diagnosis was unsure at re-evaluation, cases were missing or too 
little material was left to be representative of the tumour or the patients registered with IP tumours 
were not found in the medical records. Excluded cases did not differ significantly regarding sex and 
age at diagnosis.
HPV prevalence and p16 overexpression
12 of the 98 tumours (12.2%) were HPV DNA positive. 11 had low-risk HPV (HPV 6 and 11) 
and one had high-risk HPV (HPV 45). Of all 98 specimens, only the HR HPV specimen had a 
p16-overexpression (>70% positive cells). 
Patients with HPV positive tumours were significantly younger (mean age 45.6 years vs. 59.6 years, 
p = 0.003). In the histopathological reports the HPV positive tumours were described more often 
with areas of mild to moderate dysplasia compared to the HPV negative tumours (25.0% vs. 8.1%) 
although this difference was not statistically significant. Two patients with HPV negative IPs were 
diagnosed with SCC.
CD8 and Foxp3 immune cell infiltration
Patients with HPV positive lesions showed a tendency of higher infiltration of Foxp3 positive 
lymphocytes as compared to HPV negative lesions. However, this difference was not statistically 
significant. No differences in Foxp3 infiltration or CD8 positive immune cell infiltration or 
CD8/Foxp3 ratio were observed with regard to dysplasia. Nor were there any differences 
regarding CD8 positivity or CD8/Foxp3 ratio and HPV status.
Recurrence, HPV status and immune cell infiltration
Among the patients included in the study, the follow-up time ranged from 0-12 years with a 
median of 5 years. 40/98 (40.8%) patients had a recurrence of their IP. 10/98 patients (11.2%) had 
their first recurrences after 5 years or more even though 40 patients were lost to follow up.  
Patients with reported positive or uncertain surgical margins had a significantly higher recurrence 
rate as compared to patients with reported radical surgery (log-rank test p=0.001). The hazard ratio 
(HR) for recurrence for tumours with negative compared to positive surgical margins was 0.36 (95% 
CI 0.18-0.71). Adjustment for age, gender or HPV did not affect the HR in the multivariable analysis. 
Among patients with reported radical surgery, 17.8% of patients had recurrences within 5 years and 
6.7% after 5 years or more.
Patients with HPV positive lesions tended to have a lower 5-year recurrence rate, but this was not 
a significant difference (log-rank test: p = 0.17). 
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PAPER IV
EGFR
57.1% of the specimens expressed EGFR and the range of EGFR expression was 0-90%. 91.7% 
of HPV positive IPs expressed EGFR, as compared to 52.3% of HPV negative IPs (p=0.01) and 
the median proportion of EGFR-positive cells in HPV positive tumours was also higher than in 
HPV-negative tumours (35% vs. 10%, p<0.010). Age or gender did not influence the results. No 
statistically significant association was seen between EGFR-positivity and recurrence. There was no 
difference in EGFR expression in relation to dysplasia.
Stathmin
Staining for stathmin failed for two tumour specimens. Therefore, 96 tumours were included for 
analyses. All IPs expressed stathmin and the range of stathmin positive tumour cells was 10-100%, 
with a median expression of 20%. Stathmin expression was further categorized into low and high 
expression with 50% as a cut-off level. In total, 15.6% of the tumours had high expression of stathmin. 
A higher proportion of IPs with dysplasia had a high expression of stathmin as compared to 
those without dysplasia (40.0% vs. 12.6%, p=0.045). When analysing the relation between stathmin 
expression and recurrence, patients with IPs with high expression of stathmin tended to have earlier 
recurrences, than those with a low stathmin expression although this difference was not statistically 
significant (log rank test: p=0.053).
No difference in level of stathmin expression in HPV positive as compared to HPV negative IPs 
(27.3% vs 30.2%, p=0.25) was observed. Nor did age or sex influence the level of expression of 
stathmin. 
Besides tumour tissue, 73 of 96 slides also contained normal mucosa. The mucosa in 28 of 73 slides 
(38.4%) did not express stathmin and in the remaining slides (61.6%), the mucosa expressed stathmin 
weakly, far from strong cytoplasmic staining which was the definition of positive stathmin staining 
in the study.
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DISCUSSION
The aim of this thesis was to investigate the epidemiology and prognosis of IP and prognostic factors 
for IP on a population basis. Moreover, the aim was to investigate epidemiological aspects of SNM 
in the Swedish population as a background information to the epidemiology of IP. The development 
and behaviour of IP is still relatively unknown and under debate. With this thesis, the knowledge of 
this rare tumour has hopefully increased somewhat.
Epidemiology and prognosis of SNM (Paper I)
This study is one of few, large population based studies of SNM in recent years. According to the 
results, the incidence of SNM has decreased in Sweden during the study period (1960- 2010). 
However, the incidence of SNMMs increased significantly. A slight tendency towards an improved 
5-years relative survival of patients with SNM over the last 50 years was also found.
 
The most frequent sinonasal malignancy during the study period was SCC followed by adeno- 
carcinoma. The same relation was shown in other population-based studies [1, 2, 6] . However, 
when comparing incidences over time, SCC was still the most common malignancy but SNMM, 
became the second most common tumour at the end of the study period. This increase in incidence of 
SNMM has also been observed in other investigations [7, 136]. The difference in distribution of the 
different histological types might reflect an actual change of incidences but can also be influenced by 
improved histopathological methods. New diagnostic tools such as immunohistochemistry, intro- 
duced in the 1980s, and analyses of oncoproteins and other tumour markers, mostly introduced in the 
1990s onwards, have increased the accuracy of identification of certain tumours. Therefore, tumours 
that were classified as undifferentiated in 1960 are now likely to have acquired a specific histological 
diagnosis. For SNMMs there still seems to be a real increase in incidence [7]. 
The decrease in other SNMs in this study, similar to other studies, could be related to a decrease in 
etiological factors. For SCC, reduced smoking and a reduction in occupational exposures such as 
formaldehyde and for adenocarcinomas reduced levels of hard wood and leather dust (related to 
better working conditions) may be reflected in the decrease in incidence [2, 6, 8, 9, 137]. 
The increasing proportion of SNMs originating from the nasal cavity corresponds to observations 
in other studies [1, 2, 6, 138]. The reason for this is unknown. Possibly better diagnostic tools (such 
as endoscopy, CT and MRI) and earlier diagnosis (due to diminished doctors’ and patients’ delay), 
at the end of the study period as compared to the beginning of the study period, could give a more 
reliable origin of the tumour with reduced misclassification. Some of the tumours in the nasal cavity 
(SCC and SNMM) may have been misclassified as they might have originated from the skin in the 
vestibulum nasi. The increased proportion of tumours originating from the nasal cavity may also be 
related to the increase of SNMMs which were more common in the nose than in the paranasal sinuses.
A significantly better survival for patients with tumours originating from the nasal cavity compared 
to other location, consistent with other studies, was found [1, 139]. Presumably this relates to the fact 
that tumours in the nasal cavity generate symptoms, such as nasal blockage earlier and therefore are 
diagnosed earlier. There is a slight increase in relative 5-year survival for SNMs, possibly related to 
the shift with more tumours originating from the nasal cavity. However, new treatment strategies and 
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modern diagnostic tools, seem not to have significantly ameliorated treatment outcome but possibly, 
they may have reduced therapy-related side effects. Unfortunately, there was no data on how the 
tumour stage of the different SNMs changed over the study period and how this may have influenced 
the results.
The strengths of this study are the size, and that it is based on data from a nationwide population based 
cancer registry, the SCR, with a uniquely high coverage rate [131, 140]. The weakness is that due to 
the rarity of SNM, and especially some of the histological types, conclusions may be difficult to draw. 
Epidemiology and prognosis of Inverted Papilloma (Paper II)
This population-based study covering the Swedish population from 1960-2010, found that the age 
standardised incidence of IP increased by approximately 400%, from 0.01 to 0.33/100000 py. 
An over-representation of SCC among patients with IP (SIR 142.76, p <0.005) was also found. 
Interestingly, for patients with IP, the malignant transformation only occurred in men, in a 
proportion of 1.88 % which corresponds to a 300-fold increased incidence compared to the general 
male population. 
In our study, two individuals (18%) with IP had synchronous SCC and nine (82%) had metachronous 
SCC. The results regarding the incidence of IP are roughly similar to hospital based data presented 
from Denmark and in a European position paper on the endoscopic management of sinonasal tumours 
[26, 39]. There are, however, some differences. These could be due to chance but may also show 
the advantage of a higher coverage in a population- based study otherwise to less accurate histo- 
pathological diagnosis or under-reporting to the SCR. 
IP increased over time as opposed to SNMs (SNMMs excluded) which in the first paper were found 
to decrease during the same time-period [141].  However, the results could be influenced by an under- 
reporting to the SCR during the earlier part of the study period. This could also be explained by 
a higher detection rate of IP because of a better awareness of IP among ENT physicians in the 
recent decades and also by the increased use of endoscopic sinus surgery for diagnosis and 
treatment.  Another possible explanation is that over time more sinonasal biopsies were sent for histo- 
pathological assessment which signifies that an increased number of tumours could be reported to the 
SCR by the pathologists. Histopathological evaluations have generally improved over time and this 
may also have led to an increased reporting to the SCR. The accuracy of the SCR has been studied 
for malignant tumours [130, 131]. IP is considered a precancerous lesion and the accuracy of the 
reporting of IP has not been studied per se. The reporting rate for IP may, therefore, be lower than for 
true malignant lesions, especially in the beginning of the study period. There may however also be 
some unidentified aetiological factor that partly explains the increase in incidence of IP. 
As for the risk of malignant transformation of IP, diverging results have previously been 
reported to range from 1–53 %, where most studies have reported a considerably higher proportion of 
malignant transformation than the 1.35 % that was found in this population-based study [142-146].  This 
discrepancy may be explained by the fact that earlier hospital-based studies from referral centres 
could have studied patients with larger, more aggressive or recurrent IP tumours, where smaller or 
less aggressive IPs might not have been included. It may also be due to differences in populations 
on which the studies have been conducted. There is also a risk that our lower reported proportion of 
malignant transformation among IP is caused by an underreporting of IP in specimens of SCC. This 
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would both give an incorrectly low incidence rate of IP and an incorrectly low rate of synchronous 
SCC among IPs. However, a true comparison between studies on different populations would require 
new studies presenting SIR, since difference in age or gender distribution may differ. 
Conducting a register study with a register covering a whole population is a strength. However, we 
cannot be asserted that the coverage of IP is as high as for malignant tumours especially regarding 
the reporting of IPs with synchronous SCCs and this could affect the analyses. Furthermore, when IP 
specimens were re-evaluated in paper III and IV, six cases of exophytic papilloma reported to the SCR 
as IP were found. Among the 814 diagnosed IPs found in the register, it must be suspected that there 
are other such misclassified cases.
IP, HPV and infiltration of CD8 positive and Foxp3 positive TILs (Paper III)
In paper III, the proportion of HPV positive IPs was fairly low compared to proportions reported 
in other studies[111]. Patients with HPV positive IPs seemed to differ in that they were younger at 
diagnosis and tended to have higher infiltration of Foxp3+ TILs. Moreover, only the HR HPV positive 
specimen was p16 positive. Also, in this study, the recurrence-rate was higher in patients who had 
not undergone radical surgery, which was expected, and a considerable proportion of all recurrences 
occurred after more than five years after surgery. 
 
Among patients diagnosed with IP in Stockholm 12.2% had HPV positive tumours. This proportion 
is lower than in many other studies. In a meta-analysis from 2013, Syrjanen and Syrjanen found the 
point-estimate for HPV prevalence to be 37.8% with prevalence ranging from 0-100% [111]. There 
are different possible explanations regarding which factors that might influence these differences in 
HPV prevalence, such as HPV detection method (in situ hybridization, p16-analysis, PCR) or the 
size of the study [111]. The prevalence of HPV and HPV positive tumours can also differ in different 
study populations from different geographical regions as has been reported for HPV prevalence in 
tumours in other anatomical sites [147]. The increase in incidence of IP and in parallel, the increase 
of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) brings up the question of whether 
the increased incidence of IP is related to HPV as it is for OPSCC [148]. However, because IP is 
such a rare tumour and the proportion of HPV-positive tumours is low, it is difficult to assess if the 
incidence of HPV-positive tumours is increasing or not. An international collaboration with a larger 
study-population would be required for such research.
Furthermore, misclassification is a plausible cause for differences in proportion of HPV- positive IP 
since there are histological resemblances between IP and other types of sinonasal papilloma where 
exophytic papilloma have a stronger association to HPV [111]. Occasionally, there are uncertainties 
in regard to what kind of papilloma a study is really referring to. Like in previous studies, we found 
that LR HPV-6 and HPV-11 were the most frequent types [149-151]
Moreover, p16-positivity was only found in the one IP specimen that was HR HPV positive. 
This might indicate a possible correlation between HR HPV and p16 positivity in IP as has been 
demonstrated in OPSCC. Rooper et al. found such a correlation for inverted papilloma as opposed to 
Kim et al  [88, 152]. However, in the latter study, the cut-off for p16 positivity was set at a lower level 
(10%). P16 positivity is of course dependant of the cut-off of level. A level of 70% has been validated 
for OPSCC and should most likely be the same for IP  [132, 153]. Since only one specimen was HR 
HPV positive in our study conclusions cannot be drawn and more studies on p16 and HPV are needed 
to analyse if p16 can serve as a surrogate marker for HR HPV in IP. 
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Patients with HPV positive IPs differed from patients with HPV negative tumours in that they were 
diagnosed with IP at a significantly lower age. Patients with HPV positive IP more often had tumours 
with reported light to moderate dysplasia and a higher infiltration of Foxp3+ TILs than patients with 
HPV negative IPs. However, these differences were not statistically significant. This might be related 
to the small number of HPV positive IPs in the study. Patients with HPV positive IPs had a higher 
proportion of radical surgery according to the medical reports. This might indicate that their tumours 
were less extensive or less aggressive as has previously has been suggested for sinonasal SCCs [91]. 
Moreover, conclusions regarding the correlation between HR HPV and prognosis in IP could not be 
drawn since only one HR HPV tumour was found. 
A majority of studies conducted to compare HPV prevalence in normal mucosa and in nasal polyps 
could not detect HPV in normal mucosa. [154-157]. 
Presence of HPV in IP and differences in patient and tumour characteristics in HPV positive 
compared to HPV negative tumours in this study might suggest that HPV has some causative effect 
in the HPV positive IPs.
Furthermore, this study aimed to assess if, as has been hypothesised for OPSCC, HPV stimula-
tes an effective anti-tumoural response comprising activation of CD8+ cells and Foxp3+ cells or 
a high CD8+/Foxp3+ ratio affecting the prognosis of IP tumours [103, 115, 158]. It has previously 
been shown that IP induces a marked immune response. [29, 159, 160]. This study found an over- 
expression of Foxp3 in HPV positive IPs as compared to HPV negative tumours but the difference 
was not statistically significant. The difference might however have reached statistical significance if 
the HPV positive tumours were more numerous. A potential statistically significant difference could 
have indicated an activation of the immune system by the HPV virus. However, regarding prognosis, 
no statistically significant differences in expression of Foxp3, CD8+ or the CD8+/Foxp3+ ratio were 
found in patients with dysplasia or recurrence compared to those without. 
The recurrence rate, 40.8%, was high compared to previous studies [78, 161]. This is partly caused 
by the inclusion criteria where included patients could have unknown or unexpected IP histology 
and where surgery sometimes was undertaken only for diagnostic purpose thus leading to a partial 
resection of the tumour. The recurrence rate was significantly lower in patients who had negative 
surgical margins (23%). Notwithstanding, the still relatively high recurrence rate may partly be due 
to the surgical technique [162]. The high recurrence rate was also influenced by the, for some cases, 
long follow-up time where 10% of the recurrences occurred after five years. 17.8% of the patients 
who were reported to have undergone radical surgery had recurrences within 5 years from diagnosis. 
This is assumedly the proportion that should be compared to results from other studies reporting 
recurrences in IP where the diagnosis was known before surgery and the follow-up time did not 
exceed 5 years. 
Limitations in this study were that the study population and the different subgroups were relatively 
small. Secondly, the recurrence rate of the whole study population is probably overestimated, due to 
the study design where patients having surgical diagnostic resections were considered having under-
gone surgery. However, there is also a considerable strength in that there was no referral bias, since 
the study was population-based. 
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IP and EGFR and Stathmin Positivity (Paper IV)
A significantly higher expression of EGFR was found in HPV positive compared to HPV negative 
tumours. Furthermore, a significant association between high expression of stathmin and dysplasia 
and also a tendency towards an association between stathmin and recurrence in IP were observed.
Like in previous studies with a similar EGFR-positivity definition, EGFR expression was higher 
in HPV positive than in HPV negative IPs [163-165].This might strengthen the hypothesis, that 
there are IPs where HPV infection is an aetiological factor, possibly among others, that generates a 
different entity of IPs than the HPV negative tumours. Possibly by increasing expression or activation 
of EGFR protein since it has been proposed elsewhere that in tumours harbouring LR HPV types, 
the E5 oncoprotein plays an important role in the oncogenic transformation of the tumour, mainly by 
stimulating the EGFR pathway signalling [87, 95, 128].
Moreover, it has been reported that HPV negative specimens had EGFR mutations and that IP 
associated SCCs possibly require either overexpression or mutation of EGFR [128]. Also, a tendency 
of higher expression of EGFR has been reported in IPs with carcinomas than in IPs without [164]. 
It has been suggested that EGFR-inhibitors could be tested in LR HPV positive IP’s but considering 
the costs and side effects of such treatment, administration of EGFR- inhibitors should probably be 
reserved for patients with EGFR-positive IPs with either malignant transformation or with extra- 
sinonasal growth where radical surgery would be too mutilating [163]. Irreversible EGFR-inhibitors 
have been tested in vitro on SCC derived from IP with promising results [127].
Association between EGFR expression and light to moderate dysplasia was not found. A recent 
study reported increased EGFR expression in IP with severe dysplasia and in IP with associated SCC 
as compared to normal mucosa and also compared to IP with mild to moderate dysplasia. However, 
there was no comparison with IPs without dysplasia [87]. In this study, there were unfortunately 
no specimens with reported severe dysplasia which would have been beneficial to the study. No 
association between expression of EGFR and recurrence was found. 
27% of the HPV positive IPs were stathmin positive which of course was related to the cut-off level 
for stathmin positivity (50%) in the study. For stathmin, there does not seem to be any consensus 
regarding this cut-off level as there is for p16 positivity. Levels for stathmin positivity vary in 
different studies [166, 167]. A cut-off level of 50 % was chosen in this investigation in respect to the 
distribution in the study population and because it has previously been used as a cut-off level, among 
others [168, 169]. We did not include grading of intensity of staining as a parameter in the assessment 
of stathmin positivity which might have influenced the results.
Stathmin was more intensely expressed in the tumours as compared to the normal mucosa, which 
showed no, or very weak stathmin staining. This is in line with results from a previous study [129]. 
We also found a higher expression of stathmin among specimens with dysplasia than in specimens 
without and there was the same tendency for stathmin in recurring and non-recurring tumours. These 
results are also similar to what has been found in reports on malignant tumours such as oesophageal 
and hypopharyngeal cancer, where a high stathmin expression seems to be correlated to a poorer 
prognosis [170, 171]. If these results could be reproduced, stathmin could be a be a possible marker 
of prognosis or even a treatment target for recurring cases or tumours which, because of their extent 
or closeness to vital structures, are surgically challenging.
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CONCLUSIONS
The main findings of the thesis were:
• The overall incidence of sinonasal malignancies has decreased in Sweden from 
1960 to 2010. However, the incidence of sinonasal malignant melanomas has 
increased during the same period. SNMM is now the second most common 
SNM in Sweden.
• There was a trend towards better survival for all SNMs except undifferentiated 
carcinoma during the time-period. 
• There was a more than tenfold increase of incidence of IP in Sweden 1960-2010.
• In this population-based study, the risk of malignant transformation of IP was 
lower than previously has been presented but significantly higher than the risk 
of being diagnosed with SCC in the general population.
• Infiltration of Foxp3+ and CD8+ TILS alone or in combination with HPV did 
not affect the prognosis of IP significantly.
• Patients with HPV positive IP were diagnosed at an earlier age than HPV 
negative tumours and HPV positive IP showed a non-statistically significant 
tendency of a higher proportion of dysplasia and later recurrences. HPV 
      positive IP also had a significantly higher expression of EGFR.
• Normal mucosa adjacent to the tumours expressed stathmin weakly or not at 
all. IPs with high expression of stathmin had significantly higher proportion 
of dysplasia and a trend towards earlier recurrence was observed. HPV-status 
did not affect the stathmin expression. 
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FUTURE PERSPECTIVES
Inverted papilloma is a rare tumour and one of the aims in this thesis was to assess its incidence on a 
population basis using the SCR. However, more population-based studies are needed to confirm the 
results. Preferably they should present SIRs for an optimal between-populations comparison.
A relatively low proportion of IPs associated with SCC and especially few synchronous malignancies 
were found. This could be an effect of pathologists not registering IP when there is synchronous SCC 
in a same specimen. Therefore, analyses of SCCs in the Stockholm Biobank to investigate if they also 
harbour non-reported IP would be valuable.
Since IP is a rare tumour, larger interregional and international studies are needed to analyse the 
interaction between the immune system and the tumour. It is possible that, like in other studies, 
statistical significance was not reached because of the relatively low number of cases analysed in 
the different subgroups in the study-population. Likewise, larger studies are required to assess the 
correlation of high risk HPV and p16.
Furthermore, the proportion of HPV-positive tumours is expected to decline over time with the 
introduction of vaccines. These cover the most frequently found HPV types in IP (both high risk 
and low risk types) why a shift towards more HPV negative IPs in the future should be expected. If 
HPV positive tumours have a different behaviour and prognosis than the HPV-negative tumours, the 
eventual disappearance of HPV positive tumours will affect the overall prognosis of IP. For rare 
recurring or inoperable cases among the non-HPV driven tumours, it would be beneficial to study 
treatment targets, such as stathmin or other markers in order to possibly introduce medical treatment 
for these selected cases.
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POPULÄRVETENSKAPLIG SAMMANFATTNING PÅ SVENSKA
Inverterat papillom (IP) är en godartad tumör som utgår från slemhinnan i näsa och bihålor. 
Tumören har fått sitt namn efter den histologiska bilden som man ser vid mikroskopisk undersökning 
av vävnaden där en förtjockad slemhinna växer ner med tjocka kolvar i den underliggande vävnaden. 
Inverterat papillom är en ovanlig tumör men riktigt hur ovanlig den är har man inte vetat då de studier 
som gjorts inte baserat sig på hela befolkningar utan endast på de patienter som remitterats till vissa 
sjukhus. Män drabbas ca tre gånger så ofta som kvinnor medan barn och ungdomar sällan drabbas. 
Inverterat papillom är oftast ensidigt och vid klinisk undersökning ter det sig som en rödgråaktig 
oregelbunden, lättblödande massa. Tumören kan växa igenom ben och brosk och därmed växa 
utanför näsa och bihålor in i till exempel ögonhåla och skallbas. Behandlingen utgörs idag nästan 
uteslutande av kirurgi.
Inverterat papillom har en tendens att återkomma och återfall beror till stor del på den kirurgiska 
radikaliteten, dvs hur väl man har fått bort hela tumören. Vilka övriga faktorer som påverkar återfalls-
risken är inte känt. Tumören klassificeras som ett förstadium till cancer. Tidigare studier har visat att 
skivepitelcancer har funnits samtidigt eller uppkommit senare hos i snitt 10 % av patienterna. 
Bakomliggande orsaker till inverterat papillom är okända men man har spekulerat i att allergi, kronisk 
bihåleinflammation, luftföroreningar och virusinfektioner bidrar till uppkomsten av tumören. HPV 
(humant papillomvirus) har föreslagits som riskfaktor på grund av orsakssambandet mellan HPV 
och papillom (vårtor) huden och i slemhinnan i strupen och svalget samt sambandet mellan HPV och 
cancer och förstadium till cancer i svalget, i genitalierna och kring anus. De relativt få studier som är 
gjorda på inverterat papillom och HPV har dock inte givit någon entydig bild. 
Cancer i näsa och bihålor är en sällsynt cancerform i Sverige och orsakar idag cirka 0–1% av alla 
cancerfall och utgör cirka 5% av all huvudhalscancer. Hur förekomsten av cancer i näsa och bihålor 
har utvecklats över tid i Sverige är inte känt sedan tidigare. 
I avhandlingens första delarbete undersökte vi hur insjuknandet i cancer i näsa och bihålor har 
förändrats från 1960–2010 i hela den svenska befolkningen med hjälp av det svenska cancerregistret. 
Vi fann att insjuknandet i näs- och bihålecancer minskat något generellt men att maligna melanom 
i näsa och bihålor ökat under denna period. Fem-årsöverlevnaden har endast marginellt förbättrats 
under undersökningsperioden.
I andra delarbetet analyserade vi, också med hjälp av cancerregistret, hur insjuknandet i IP har 
förändrats över tid och hur många av dem som egentligen blir elakartade. Vi fann att insjuknandet 
ökat markant över tid men att övergången till cancer var lägre än vad som tidigare rapporterats.
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I det tredje delarbetet ville vi utröna om vi kunde hitta något samband mellan IP och HPV samt om 
infiltration av vissa immunförsvarsceller (så kallade CD8-positiva och Foxp3-positiva celler) i 
tumören hade någon påverkan på prognosen. I vår studie skiljde sig patienter med HPV förekomst från 
de som inte hade HPV i sina tumörer på flera sätt vilket kan tyda på att HPV påverkar tumörens 
uppkomst och beteende. Däremot verkade inte immunförsvarscellerna närvaro påverka tumörens 
prognos nämnvärt.
I det sista delarbetet analyserade vi uttryck av två proteiner, EGFR och stathmin, är relaterade till 
cellcykeln. När de är överuttryckta (producerade i överskott) eller är muterade (förändrade) kan de 
bidra till utvecklingen av en vanlig cell till en cancercell.  Resultaten visade att det fanns en relation 
mellan HPV och EGFR i IP medan stathmin verkade vara associerat med tumörernas prognos för hela 
gruppen IP.
Sammanfattningsvis fann vi att inverterat papillom är en ovanlig tumör som ökar i förekomst. 
Det finns en liten risk att den omvandlas till en elakartad tumör. HPV kan kanske bidra till dess 
utveckling och då möjligen genom överuttryck av ett visst protein, EGFR. Ett annat protein, 
stathmin, kan till synes också påverka tumörens beteende. Förhoppningsvis kan man i framtiden 
behandla IP med mediciner som riktar sig mot dessa eller andra proteiner men mer forskning 
inom detta område behövs. Vi fann även att insjuknandet i de flesta cancerformer i näsa och bihålor 
minskat i Sverige sedan 1960 talet men insjuknandet i malignt melanom i näsa och bihålor har ökat. 
Tyvärr har inte prognosen för näs- och bihålevcancer förbättrats nämnvärt.
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